| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
46,511,000 |
| Market
Cap: |
13.02(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.2799 - $0.2799 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile OpGen is a precision medicine company. Along with its subsidiaries, Curetis GmbH and Ares Genetics GmbH, Co. is developing and commercializing molecular microbiology solutions helping to guide clinicians with actionable information about life threatening infections. Co.'s existing product portfolio includes Unyvero, Acuitas Antimicrobial Resistance Gene Panel, and the ARES Technology Platform including ARES reference database on antimicrobial resistance, using next generation sequencing technology and artificial intelligence-powered bioinformatics solutions for antibiotic response prediction, as well as the Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kit.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Dec Timothy C |
Chief Financial Officer |
• – – |
2017-11-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,250 |
125,216 |
|
- |
|
| Ushio Misti |
Director |
– • – |
2017-08-25 |
4 |
A |
$0.00 |
$0 |
D/D |
39,292 |
39,292 |
|
- |
|
| Harris Timothy J.r. |
Director |
– • – |
2017-08-25 |
4 |
A |
$0.00 |
$0 |
D/D |
39,292 |
89,408 |
|
- |
|
| Dandrea Harry J |
Director |
– • – |
2017-08-25 |
4 |
A |
$0.00 |
$0 |
D/D |
39,292 |
39,292 |
|
- |
|
| Jones Evan/ Fa |
Chief Executive Officer |
• – – |
2017-07-18 |
4 |
B |
$0.40 |
$750,000 |
D/D |
1,875,000 |
5,680,604 |
2.74 |
- |
|
| Dec Timothy C |
Chief Financial Officer |
• – – |
2017-07-18 |
4 |
B |
$0.40 |
$26,000 |
D/D |
65,000 |
118,966 |
2.74 |
- |
|
| Dec Timothy C |
Chief Financial Officer |
• – – |
2016-11-10 |
5 |
OE |
$0.00 |
$0 |
D/D |
6,250 |
53,966 |
|
- |
|
| Merck Global Health Innovation Fund, Llc |
10% Owner |
– – • |
2016-06-27 |
4 |
A |
$0.00 |
$0 |
I/I |
2,734,427 |
5,413,449 |
|
- |
|
| Merck Global Health Innovation Fund, Llc |
10% Owner |
– – • |
2016-05-19 |
4 |
A |
$0.00 |
$0 |
I/I |
1,200,000 |
2,679,022 |
|
- |
|
| Harris Timothy J.r. |
Director |
– • – |
2016-05-19 |
4 |
B |
$0.00 |
$0 |
D/D |
43,716 |
50,116 |
2.31 |
- |
|
| Jven Capital, Llc |
10% Owner |
– – • |
2016-05-19 |
4 |
B |
$0.00 |
$0 |
D/D |
874,317 |
3,805,604 |
2.37 |
- |
|
| Jones Evan/ Fa |
Chief Executive Officer |
• • • |
2016-05-19 |
4 |
B |
$0.00 |
$0 |
I/I |
874,317 |
3,805,604 |
2.56 |
- |
|
| Krenitsky Kevin |
President |
• – – |
2016-05-19 |
4 |
B |
$0.00 |
$0 |
D/D |
43,716 |
52,050 |
2.66 |
- |
|
| Dec Timothy C |
Chief Financial Officer |
• – – |
2016-05-19 |
4 |
B |
$0.00 |
$0 |
D/D |
43,716 |
47,716 |
2.66 |
- |
|
| Jones Evan/ Fa |
Chief Executive Officer |
• • • |
2015-12-07 |
4 |
B |
$1.79 |
$1,073 |
I/I |
600 |
2,930,032 |
2.56 |
- |
|
| Jones Evan/ Fa |
Chief Executive Officer |
• • • |
2015-12-04 |
4 |
B |
$1.76 |
$527 |
I/I |
300 |
2,929,432 |
2.56 |
- |
|
| Merck Global Health Innovation Fund, Llc |
10% Owner |
– – • |
2015-07-14 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
1,479,022 |
|
- |
|
| Versant Side Fund Iii, L.p. |
10% Owner |
– – • |
2015-05-08 |
4 |
A |
$0.00 |
$0 |
I/I |
2,068,286 |
14,997 |
|
- |
|
| Versant Side Fund Iii, L.p. |
10% Owner |
– – • |
2015-05-08 |
4 |
B |
$6.00 |
$2,479,992 |
I/I |
413,332 |
2,853 |
1.5 |
- |
|
| Krenitsky Kevin |
President |
• – – |
2015-05-08 |
4 |
B |
$6.00 |
$50,004 |
D/D |
8,334 |
8,334 |
2.74 |
- |
|
| Ushio Misti |
Director |
– • – |
2015-05-08 |
4 |
A |
$0.00 |
$0 |
I/I |
1,079,080 |
1,409,796 |
|
- |
|
| Ushio Misti |
Director |
– • – |
2015-05-08 |
4 |
B |
$6.00 |
$1,804,998 |
I/I |
300,833 |
330,716 |
2.1 |
- |
|
| Howe Timothy |
Director |
– • – |
2015-05-08 |
4 |
A |
$0.00 |
$0 |
I/I |
320,011 |
388,328 |
|
- |
|
| Howe Timothy |
Director |
– • – |
2015-05-08 |
4 |
B |
$6.00 |
$75,000 |
I/I |
12,500 |
68,317 |
2.1 |
- |
|
| Jven Capital, Llc |
10% Owner |
– – • |
2015-05-08 |
4 |
A |
$0.00 |
$0 |
D/D |
2,484,132 |
2,929,132 |
|
- |
|
89 Records found
|
|
Page 3 of 4 |
|
|
